1
|
Olmez OF, Bilici A, Gursoy P, Cubukcu E, Sakin A, Korkmaz T, Cil I, Cakar B, Menekse S, Demir T, Acikgoz O, Hamdard J. Impact of systemic inflammatory markers in patients with ALK-positive non-small cell lung cancer treated with crizotinib. Pulmonology 2023; 29:478-485. [PMID: 36564237 DOI: 10.1016/j.pulmoe.2022.11.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2022] [Revised: 11/23/2022] [Accepted: 11/24/2022] [Indexed: 12/24/2022] Open
Abstract
OBJECTIVES To evaluate the prognostic utility of inflammation-based prognostic scores in patients with ALK-positive metastatic or non-resectable non-small-cell lung cancer (NSCLC) treated with crizotinib. PATIENTS AND METHODS A total of 82 patients with ALK-positive metastatic or non-resectable NSCLC who received ALK TKI crizotinib were included. Pre-treatment modified Glasgow prognostic score (mGPS), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII) were calculated. Multivariable logistic regression and Cox proportional hazards models were used to assess the impact of pretreatment mGPS, PNI, and SII on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). RESULTS The ORR was 77.2%, while 1-year OS and PFS rates were 95.0% and 93.5%, respectively. The univariate analysis revealed significantly higher 1-year PFS (89.4 vs. 64.4%, p=0.043) and OS (92.0 vs. 83.3%, p=0.01) rates in patients with low (<934.7) vs. high (≥934.7) SII scores. Multivariate analysis revealed that PNI ≥0.09 was a significant determinant of poorer 1-year OS rates (hazard ratio [HR]: 2.46, 95% confidence interval [CI] 0.88-4.85, p=0.035). No significant difference was observed in survival rates according to gender, age, smoking status, prior lines of therapy, or mGPS scores, while higher mGPS scores (odds ratio [OR]: 0.1, 95%CI 0.16-1.04; p=0.009) and higher PNI scores (OR: 0.16, 95% CI 0.02-0.55; p=0.035) were associated with poorer ORR. CONCLUSION Our findings indicate the prognostic significance of PNI and SII in terms of survival outcome and the impact of mGPS and PNI on treatment response in patients with ALK-positive NSCLC treated with crizotinib.
Collapse
Affiliation(s)
- O F Olmez
- Department of Medical Oncology, Medipol University Faculty of Medicine, Istanbul, Turkey
| | - A Bilici
- Department of Medical Oncology, Medipol University Faculty of Medicine, Istanbul, Turkey
| | - P Gursoy
- Ege University Faculty of Medicine, Izmir, Turkey
| | - E Cubukcu
- Uludag University Faculty of Medicine, Bursa, Turkey
| | - A Sakin
- University of Health Sciences Okmeydani Training and Research Hospital, Istanbul, Turkey
| | - T Korkmaz
- Acıbadem University Faculty of Medicine, Istanbul, Turkey
| | - I Cil
- Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
| | - B Cakar
- Ege University Faculty of Medicine, Izmir, Turkey
| | - S Menekse
- Bagcilar Training and Research Hospital, Istanbul, Turkey
| | - T Demir
- Bezmialem University Faculty of Medicine, Istanbul; Turkey
| | - O Acikgoz
- Department of Medical Oncology, Medipol University Faculty of Medicine, Istanbul, Turkey
| | - J Hamdard
- Department of Medical Oncology, Medipol University Faculty of Medicine, Istanbul, Turkey.
| |
Collapse
|
2
|
Isıkdogan A, Turk H, Bilir C, Şendur M, Karabulut B, Artac M, Cicin I, Geredeli C, Alacacioglu A, Kefeli U, Harputluoglu H, Bozkurt O, Cubukcu E, Tural D, Sakin A, Cil T, Dane F, Çevik D, Arslan Ç, Karadurmus N, Gumus M, Yalcin S. P-90 First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
3
|
Artac M, Cubukcu E, Bozkurt O, Bilici A, Celik S, Ozcelik M, Oven B, Simsek E, Geredeli C, Karaca M, Cil T, Harputluoglu H, Şendur M, Turk H, Kefeli U, Alacacioglu A, Tural D, Sakin A, Karadurmus N, Çevik D, Dane F, Gumus M. P-92 Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.182] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Erol C, Basoglu T, Sakin A, Ozden E, Cubuk D, Yumuk P, Dogan M, Oksuzoglu B, Yildirim H, Oner I, Karakurt Eryilmaz M, Dulgar O, Turkmen Bekmez E, Dogan N, Ozen M, Gurler F, Paksoy N, Aksoy A, Hizal M, Sendur M. 1405P Efficacy and safety of perioperative FLOT (5-FU, LV, oxaliplatin, docetaxel) chemotherapy in gastric and gastroesophageal junction adenocarcinoma: Real-life data from Turkish oncology group. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Ç. Arslan, Kefeli U, Yildirim E, Isıkdogan A, Karadurmus N, Karabulut B, Cicin I, Cubukcu E, Bilir C, Ozcelik M, Cil T, Celik S, Bozkurt O, Harputluoglu H, Oven B, Geredeli C, Tural D, Sakin A, Çevik D, Gumus M, Yalcin S. P-219 Real-life experience with chemotherapy plus biologics in first-line treatment of right-sided, RAS wild-type, metastatic colon cancer: A multicenter Onco-Colon Turkey study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Sakin A, Can O. Gastroenteropancreatic neuroendocrine carcinoma: single center experience. Hematol Transfus Cell Ther 2020. [DOI: 10.1016/j.htct.2020.09.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
7
|
Sakin A, Sahin S, Atci MM, Sakin A, Yasar N, Geredeli C, Aksaray F, Cihan S. The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer. Pulmonology 2019; 27:26-34. [PMID: 31839507 DOI: 10.1016/j.pulmoe.2019.11.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Revised: 11/14/2019] [Accepted: 11/22/2019] [Indexed: 12/28/2022] Open
Abstract
PURPOSE The aim of this study is to investigate the effect of treatment modalities on survival among unoperat ed and locally-advanced non-small cell lung cancer (NSCLC) patients aged 70 years and older, representing real-life data. METHODS From 2005 through 2017, medical records of 2259 patients with lung cancer from Okmeydani Training and Research Hospital-Istanbul/Turkey were reviewed retrospectively. Patients with locally advanced NSCLC ≥ 70 years of age who did not undergo surgery for lung cancer were reviewed. In total, 130 patients were eligible for the final analysis. Patients were stratified into four groups as: chemotherapy (CT), concurrent chemoradiotherapy (cCRT), sequential chemoradiotherapy (sCRT), and radiotherapy (RT) only. RESULTS Of the 130 patients included in the analysis; CT, cCRT, sCRT, and RT only were applied to 25(19.2%), 30(23.1%), 31(23.8%), and 44(33.8%) patients, retrospectively. Twelve (9.2%) patients were female. Median age was 72 years (range, 70-88). Sixty (46.2%) patients had stage IIIA disease and 70(53.8%) patients had stage IIIB disease. Median progression-free survival(mPFS) in patients treated with CT, cCRT, sCRT, and RT were 8.0, 15, 10, and 9.0 months, respectively(p = 0.07). Corresponding median overall survival (mOS) were 10, 33, 20, and 15 months (p = 0.04). In multivariate analysis, stage IIIB disease [hazard ratio (HR), 2.8], ECOG-PS 2(HR, 2.10), and ECOG-PS 3-4(HR, 5.13) were found to be the negative factors affecting survival, while cCRT (HR, 0.45) and sCRT (HR, 0.50) were the independent factors associated with better survival. CONCLUSION This study showed that the use of combined treatment modality was associated with better survival in elderly patients with locally advanced NSCLC, with the greatest survival observed in patients treated with cCRT. We therefore suggest that cCRT, when feasible, should be strongly considered in locally advanced NSCLC patients 70 years and over.
Collapse
Affiliation(s)
- A Sakin
- Department of Medical Oncology, Yuzuncu Yil University Medical School, 65030, Van, Turkey.
| | - S Sahin
- Department of Medical Oncology, University of Health Sciences, Van Research and Training Hospital, Van, Turkey.
| | - M M Atci
- Department of Medical Oncology, University of Health Sciences, Okmeydani Training and Research Hospital, 34384, Istanbul, Turkey.
| | - A Sakin
- Department of Internal Medicine, University of Health Sciences, Van Research and Training Hospital, Van, Turkey.
| | - N Yasar
- Department of Medical Oncology, University of Health Sciences, Okmeydani Training and Research Hospital, 34384, Istanbul, Turkey.
| | - C Geredeli
- Department of Medical Oncology, University of Health Sciences, Okmeydani Training and Research Hospital, 34384, Istanbul, Turkey.
| | - F Aksaray
- Department of Radiation Oncology, University of Health Sciences, Okmeydani Training and Research Hospital, 34384, Istanbul, Turkey.
| | - S Cihan
- Department of Medical Oncology, University of Health Sciences, Okmeydani Training and Research Hospital, 34384, Istanbul, Turkey.
| |
Collapse
|
8
|
Bilici A, Olmez O, Gursoy P, Çubukçu E, Yildiz O, Sakin A, Korkmaz T, Cil I, Cakar B, Menekse S, Demir T, Acikgoz O, Hamdard J. P2.01-64 Systemic Inflammatory Markers as a Predictors of Response to Crizotinib in Patients with ALK-Positive Non-Small-Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Olmez O, Bilici A, Gursoy P, Çubukçu E, Yildiz O, Sakin A, Korkmaz T, Cil I, Cakar B, Menekse S, Demir T, Acikgoz O, Hamdard J. P1.14-01 Are Pretreatment Inflammation-Based Prognostic Scores Useful in Predicting the Outcomes of Patients with ALK-Positive NSCLC? J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
10
|
Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes. Cancer Chemother Pharmacol 2018; 83:131-143. [PMID: 30377778 DOI: 10.1007/s00280-018-3712-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Accepted: 10/25/2018] [Indexed: 01/19/2023]
Abstract
PURPOSE In this study, we aimed to describe the real-life practice outcomes of pertuzumab-trastuzumab-taxane (PTT) combination in visceral organ metastatic, trastuzumab-naive breast cancer (BC) patients. METHODS This study was conducted by Turkish Oncology Group and included 317 patients' data from 36 centers. RESULTS Median age was 51 (22-82). Median PFS was 28.5 months, while median OS was 40.3 months. Patients with brain metastases (n: 13, 4.1%) had worse PFS (16.8 m vs. 28.5 m; p = 0.002) and OS (26.7 m vs. 40.3 m; p = 0.009). Patients older than 65 years of age (n: 42, 13.2%) had significantly lower OS results (19.8 m vs. 40.3 m; p = 0.01). Two hundred sixty-eight patients (86.7%) received docetaxel while 37 patients (11.7%) received paclitaxel. PFS and OS were similar between taxane groups. In eight patients (2.5%), 5-40% ejection fraction decrement from baseline was detected without any clinical sign of heart failure. CONCLUSIONS Our RLP trial included only visceral metastatic, trastuzumab-naïve BC patients including cases with brain involvement who received PTT combination in the first-line treatment. Regardless of negative prognostic characteristics, our results are in parallel with pivotal trial. Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment. Taxane selection can be personalized and endocrine maintenance may further improve outcomes after taxanes were discontinued. To our knowledge, this is the largest scale real-life clinical practice study of pertuzumab-trastuzumab-taxane therapy to date.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Breast Neoplasms/drug therapy
- Breast Neoplasms/mortality
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/drug therapy
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/secondary
- Carcinoma, Lobular/drug therapy
- Carcinoma, Lobular/mortality
- Carcinoma, Lobular/secondary
- Docetaxel/administration & dosage
- Female
- Follow-Up Studies
- Humans
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Metastasis
- Paclitaxel/administration & dosage
- Practice Patterns, Physicians'
- Prognosis
- Retrospective Studies
- Survival Rate
- Trastuzumab/administration & dosage
- Young Adult
Collapse
Affiliation(s)
- Ece Esin
- Department of Medical Oncology, Dr. A. Y. Ankara Oncology Education and Research Hospital, University of Health Sciences, Yenimahalle, Ankara, Turkey.
| | - B Oksuzoglu
- Department of Medical Oncology, Dr. A. Y. Ankara Oncology Education and Research Hospital, University of Health Sciences, Yenimahalle, Ankara, Turkey
| | - A Bilici
- Departmant of Medical Oncology, Medipol University International Health Center, Istanbul, Turkey
| | - I Cicin
- Department of Medical Oncology, Trakya University, Edirne, Turkey
| | - O Kostek
- Department of Medical Oncology, Trakya University, Edirne, Turkey
| | - M A Kaplan
- Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
| | - S Aksoy
- Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - B Y Aktas
- Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - O Ozdemir
- Department of Medical Oncology, Ataturk Education and Research Hospital, İzmir K.C. University, Izmir, Turkey
| | - A Alacacioglu
- Department of Medical Oncology, Ataturk Education and Research Hospital, İzmir K.C. University, Izmir, Turkey
| | - D Cabuk
- Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Izmit, Turkey
| | - A T Sumbul
- Department of Medical Oncology, Baskent University Adana Hospital, Adana, Turkey
| | - A Sakin
- Department of Medical Oncology, Istanbul Okmeydani Education and Research Hospital, Istanbul, Turkey
| | - S Paydas
- Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey
| | - E Yetisir
- Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey
| | - O Er
- Department of Medical Oncology, Acibadem Maslak Hospital, Acibadem MAA University, Istanbul, Turkey
| | - T Korkmaz
- Department of Medical Oncology, Acibadem Altunizade Hospital, Acibadem MAA University, Istanbul, Turkey
| | - N Yildirim
- Department of Medical Oncology, Dr. Ersin Arslan Training and Research Hospital, Gaziantep, Turkey
| | - T Sakalar
- Department of Medical Oncology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
| | - H Demir
- Department of Medical Oncology, Kayseri Education and Research Hospital, University of Health Sciences, Kayseri, Turkey
| | - M Artac
- Department of Medical Oncology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
| | - M Karaagac
- Department of Medical Oncology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
| | - H Harputluoglu
- Department of Medical Oncology, Turgut Ozal Medical Center, Inonu University, Malatya, Turkey
| | - E Bilen
- Department of Medical Oncology, Turgut Ozal Medical Center, Inonu University, Malatya, Turkey
| | - E Erdur
- Department of Medical Oncology, Dr. A. Y. Ankara Oncology Education and Research Hospital, University of Health Sciences, Yenimahalle, Ankara, Turkey
| | - S Degirmencioglu
- Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli, Turkey
| | - A Aliyev
- Department of Medical Oncology, Faculty of Medicine, Bezmialem University, Istanbul, Turkey
| | - T Cil
- Department of Medical Oncology, Adana City Hospital, University of Health Sciences, Adana, Turkey
| | - P Olgun
- Department of Medical Oncology, Adana City Hospital, University of Health Sciences, Adana, Turkey
| | - G Basaran
- Department of Medical Oncology, Acibadem Maslak Hospital, Acibadem MAA University, Istanbul, Turkey
| | - O Gumusay
- Department of Medical Oncology, Faculty of Medicine, Gaziosmanpasa University, Tokat, Turkey
| | - A Demir
- Department of Medical Oncology, Istanbul Okmeydani Education and Research Hospital, University of Health Sciences, Istanbul, Turkey
| | - E Tanrikulu
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - P F Yumuk
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Inanc Imamoglu
- Department of Medical Oncology, Ankara Diskapi Education and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - B Oyan
- Department of Medical Oncology, Acibadem Altunizade Hospital, Acibadem MAA University, Istanbul, Turkey
| | - B Cetin
- Department of Medical Oncology, Faculty of Medicine, RTE University, Rize, Turkey
| | - V Haksoyler
- Department of Medical Oncology, Diyarbakir G.Y. Education and Research Hospital, University of Health Sciences, Diyarbakir, Turkey
| | - N Karadurmus
- Department of Medical Oncology, Gulhane Education and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - I Erturk
- Department of Medical Oncology, Gulhane Education and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - T Evrensel
- Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey
| | - H Yilmaz
- Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey
| | - I Beypinar
- Department of Medical Oncology, Faculty of Medicine, Afyon Kocatepe University, Afyon, Turkey
| | - M Kocer
- Department of Medical Oncology, Faculty of Medicine, Isparta S.D University, Isparta, Turkey
| | - K N Pilanci
- Department of Medical Oncology, Haseki Education and Research Hospital, University of Health Sciences, Istanbul, Turkey
| | - M Seker
- Department of Medical Oncology, Ankara Bayindir Hospital, Ankara, Turkey
| | - Y Urun
- Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey
| | - N Yildirim
- Department of Medical Oncology, Numune Education and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - T Eren
- Department of Medical Oncology, Numune Education and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - U Demirci
- Department of Medical Oncology, Dr. A. Y. Ankara Oncology Education and Research Hospital, University of Health Sciences, Yenimahalle, Ankara, Turkey
| |
Collapse
|
11
|
Kılıçkap S, Ozturk A, Karadurmuş N, Korkmaz T, Yumuk P, Çiçin İ, Paydaş S, Çılbır E, Sakalar T, Uysal M, Üskent N, Demir N, Sakin A, Turhal N, Keskin S, Tural D, Eralp Y, Basal F, Yaşar H, Sendur M, Demirci U, Çubukçu E, Karaağaç M, Karaca Ş, Tatlı A, Yetisyigit T, Urvay S, Gürsoy P, Oyan Uluç B, Turna Z, Kucukoner M, Ölmez Ö, Çabuk D, Şeker M, Ünal O, Meydan N, Okutur S, Tunalı D. P1.01-45 Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
12
|
Esin E, Cakmak Oksuzoglu O, Bilici A, Cicin I, Aksoy S, Alacacioglu A, Kaplan M, Cabuk D, Sumbul A, Paydas S, Sakin A, Er Ö, Korkmaz T, Yildirim N, Artac M, Harputluoglu H, Yumuk P, Basaran G, Oyan Uluc B, Demirci U. Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.315] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
13
|
Kilickap S, Ölmez ÖF, Cicin I, Demirci U, Alan O, Cabuk D, Şakalar T, Tatlı A, Başol Buğdaycı F, Eralp Y, Uysal M, Demirkazık A, Bilgin B, Yıldız B, Karaağaç M, Okutur K, Sakin A. The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Aldemir M, Turkeli M, Hacioglu B, Sakin A, Yaman E, Coban E, Koca D, Karaca M, Simsek M, Bahceci A, Sen E, Eren T, Aliustaoglu B, Sakalar T, Kalkan N, Aktas G, Bilici M, Turhal S, Benekli M, Tekin S. Efficacy and tolerability of first-line chemotherapy in elderly patients (age ≥70 years) with metastatic gastric cancer: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw371.42] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Kutlu O, Ecirli I, Keskin M, Koçar K, Sakin A, Basturk A. PP-017 HEREDITARY HYPERFERRITINEMIA-CATARACT SYNDROME: CASE REPORT. Leuk Res 2014. [DOI: 10.1016/s0145-2126(14)70071-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Karadag S, Gursu M, Sakin A, Atalay E, Basinoglu F, Aydin Z, Uzun S, Sumnu A, Cebeci E, Koldas M, Ozturk S, Kazancioglu R. The Relationship between Soluble Tumor Necrosis Factor-like Weak Inducer of Apoptosis Levels and Cardiac Functions in Peritoneal Dialysis Patients. EUR J INFLAMM 2014. [DOI: 10.1177/1721727x1401200304] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Tumor necrosis factor (TNF)-like weak inducer of apoptosis (sTWEAK) levels has been reported to be decreased in patients on hemodialysis (HD) and patients with heart failure. We aimed to study the relationship between sTWEAK levels and cardiac functions in peritoneal dialysis (PD) patients. This cross-sectional study was carried out on patients on chronic PD programs for more than three months. Patients aged under 18 or over 80 years, patients with overt cardiac disease, overt hypervolemia, active systemic infection, malignancy, peritonitis within the last month were excluded. The patient group was compared with the control group including healthy adults aged 24–61 years. Fifty-two PD patients were included in the study (mean age: 52.7±15.4 years; female/male ratio: 30/22). The corresponding data of the control group were 41.3±10.7 years and 17/14. There was no statistically significant difference between demographic parameters of the groups except age. The mean sTWEAK level of the patient and the control groups were similar (564±17 pcg/ml vs 535±126 pcg/ml, p=0.419). No correlation was detected between any of the demographic variables and sTWEAK levels. Among the echocardiographic parameters, only ejection fraction was found to be correlated negatively with sTWEAK levels. Patients with ischemic heart disease (IHD) and heart failure had significantly higher sTWEAK levels compared with the patients without these diseases. With linear regression analysis, only age and the presence of heart failure were found to be the independent determinants of sTWEAK levels. Level of sTWEAK is significantly high in PD patients with heart failure and IHD. sTWEAK may be a marker of cardiac functions in PD patients.
Collapse
Affiliation(s)
- S. Karadag
- Haseki Training and Research Hospital, Department of Nephrology, Istanbul, Turkey
| | - M. Gursu
- Haseki Training and Research Hospital, Department of Nephrology, Istanbul, Turkey
| | - A. Sakin
- Haseki Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
| | - E. Atalay
- Haseki Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
| | - F. Basinoglu
- Haseki Training and Research Hospital, Department of Biochemistry, Istanbul, Turkey
| | - Z. Aydin
- Haseki Training and Research Hospital, Department of Nephrology, Istanbul, Turkey
| | - S. Uzun
- Haseki Training and Research Hospital, Department of Nephrology, Istanbul, Turkey
| | - A. Sumnu
- Haseki Training and Research Hospital, Department of Nephrology, Istanbul, Turkey
| | - E. Cebeci
- Haseki Training and Research Hospital, Department of Nephrology, Istanbul, Turkey
| | - M. Koldas
- Haseki Training and Research Hospital, Department of Biochemistry, Istanbul, Turkey
| | - S. Ozturk
- Haseki Training and Research Hospital, Department of Nephrology, Istanbul, Turkey
| | - R. Kazancioglu
- Bezmialem Vakif University, Medical Faculty, Department of Nephrology, Istanbul, Turkey
| |
Collapse
|